A Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 6727 Administered Intravenously in Asian Patients With Various Solid Cancers With Repeated Administration in Patients With Clinical Benefit.
Phase of Trial: Phase I
Latest Information Update: 22 Apr 2014
At a glance
- Drugs Volasertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 20 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jul 2011 Planned end date changed from 1 Jul 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 27 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.